UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 40

Sortiert nach

COPD and the Risk of Depression

Chest, 2010-02, Vol.137 (2), p.341-347

2010

Link zum Volltext

Verfügbarkeit prüfen

Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials

Respiratory medicine, 2018-10, Vol.143, p.67-73

2018

Link zum Volltext

Verfügbarkeit prüfen

Effect of long-acting β2-agonists olodaterol and formoterol on heart rate and blood pressure in chronic obstructive pulmonary disease patients

Pulmonary pharmacology & therapeutics, 2018-10, Vol.52, p.1-6

2018

Link zum Volltext

Verfügbarkeit prüfen

Chronic obstructive pulmonary disease and the risk of cardiovascular diseases

European journal of epidemiology, 2010-04, Vol.25 (4), p.253-260

2010

Link zum Volltext

Verfügbarkeit prüfen

β-Blockers in COPD: A Cohort Study From the TONADO Research Program

Chest, 2018-06, Vol.153 (6), p.1315-1325

2018

Link zum Volltext

Verfügbarkeit prüfen

Effect of long-acting β 2 -agonists olodaterol and formoterol on heart rate and blood pressure in chronic obstructive pulmonary disease patients

Pulmonary pharmacology & therapeutics, 2018-10, Vol.52, p.1

2018

Link zum Volltext

Verfügbarkeit prüfen

Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease

Respiratory medicine, 2017-01, Vol.122, p.58-66

2017

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists

Pharmacoepidemiology and drug safety, 2022-08, Vol.31 (8), p.827-839

2022

Link zum Volltext

Verfügbarkeit prüfen

No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Mode rate-to-Very-Severe COPD.(ORIGINAL RESEARCH)

International journal of chronic obstructive pulmonary disease, 2020-08, Vol.15, p.1945

2020

Link zum Volltext

Verfügbarkeit prüfen

A Post Hoc Holter ECG Analysis of Olodaterol and Formoterol in Moderate-to-Very-Severe COPD

International journal of chronic obstructive pulmonary disease, 2020-01, Vol.15, p.1955-1965

2020

Link zum Volltext

Verfügbarkeit prüfen

The Impact of Minor Perioperative Anesthesia-Related Incidents, Events, and Complications on Postanesthesia Care Unit Utilization

Anesthesia and analgesia, 1999-08, Vol.89 (2), p.506-513

1999

Link zum Volltext

Verfügbarkeit prüfen

No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Moderate-to-Very-Severe COPD

International journal of chronic obstructive pulmonary disease, 2020-01, Vol.15, p.1945-1953

2020

Link zum Volltext

Verfügbarkeit prüfen

Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD

International journal of chronic obstructive pulmonary disease, 2020-01, Vol.15, p.1935-1944

2020

Link zum Volltext

Verfügbarkeit prüfen

One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis

Chronic obstructive pulmonary disease, 2015-09, Vol.12 (5), p.484-493

2015

Link zum Volltext

Verfügbarkeit prüfen

No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study

Scientific reports, 2020-01, Vol.10 (1), p.586-586, Article 586

2020

Link zum Volltext

Verfügbarkeit prüfen

Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease

International journal of chronic obstructive pulmonary disease, 2017-01, Vol.12, p.3329-3339

2017

Link zum Volltext

Verfügbarkeit prüfen

Long-term safety of tiotropium/olodaterol Respimat ® in patients with moderate-to-very severe COPD and renal impairment in the TONADO ® studies

International journal of chronic obstructive pulmonary disease, 2018-01, Vol.13, p.1819-1831

2018

Link zum Volltext

Verfügbarkeit prüfen

Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies

NPJ primary care respiratory medicine, 2020-12, Vol.30 (1), p.53-53, Article 53

2020

Link zum Volltext

Verfügbarkeit prüfen

Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat ® device for maintenance treatment of COPD: comparison with the long-acting β 2 -agonist formoterol

NPJ primary care respiratory medicine, 2017-10, Vol.27 (1), p.60

2017

Link zum Volltext

Verfügbarkeit prüfen

Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol

NPJ primary care respiratory medicine, 2017-10, Vol.27 (1), p.1-6, Article 60

2017

Link zum Volltext

Verfügbarkeit prüfen

Effects of epinephrine and vasopressin on median fibrillation frequency and defibrillation success in a porcine model of cardiopulmonary resuscitation

Resuscitation, 1996-02, Vol.31 (1), p.65-73

1996

Link zum Volltext

Verfügbarkeit prüfen

Reflux Disease, Gastrointestinal Ulcer or Weight Loss in Patients with COPD

Chronic obstructive pulmonary disease, 2010-06, Vol.7 (3), p.172-178

2010

Link zum Volltext

Verfügbarkeit prüfen

Release of endogenous vasopressors during and after cardiopulmonary resuscitation

Heart (British Cardiac Society), 1996-02, Vol.75 (2), p.145-150

1996

Link zum Volltext

Verfügbarkeit prüfen

The Performance of Electroencephalogram Bispectral Index and Auditory Evoked Potential Index to Predict Loss of Consciousness During Propofol Infusion

Anesthesia and analgesia, 1999-11, Vol.89 (5), p.1311-1315

1999

Link zum Volltext

Verfügbarkeit prüfen

Assessment of the safety and tolerance of 6% hydroxyethyl starch (200/0.5) solution : A randomized, controlled epidemiology study

Anesthesia and analgesia, 1998-04, Vol.86 (4), p.850-855

1998

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(40)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(26)
Life Sciences & Biomedicine
(25)
Humans
(20)
Female
(15)
Aged
(14)
Chronic Obstructive Pulmonary Disease
(14)
Male
(14)
Middle Aged
(14)
Respiratory System
(12)
Adult
(9)
Patients
(9)
Anesthesiology
(8)
Biological And Medical Sciences
(8)
Medical Sciences
(8)
Cardiovascular Disease
(7)
Copd
(7)
Double-Blind Method
(7)
General & Internal Medicine
(7)
Olodaterol
(7)
Original Research
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

COPD and the Risk of Depression

Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials

Effect of long-acting β2-agonists olodaterol and formoterol on heart rate and blood pressure in chronic obstructive pulmonary disease patients

Chronic obstructive pulmonary disease and the risk of cardiovascular diseases

β-Blockers in COPD: A Cohort Study From the TONADO Research Program

Effect of long-acting β 2 -agonists olodaterol and formoterol on heart rate and blood pressure in chronic obstructive pulmonary disease patients

Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease

Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists

No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Mode rate-to-Very-Severe COPD.(ORIGINAL RESEARCH)

A Post Hoc Holter ECG Analysis of Olodaterol and Formoterol in Moderate-to-Very-Severe COPD

The Impact of Minor Perioperative Anesthesia-Related Incidents, Events, and Complications on Postanesthesia Care Unit Utilization

No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Moderate-to-Very-Severe COPD

Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD

One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis

No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study

Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease

Long-term safety of tiotropium/olodaterol Respimat ® in patients with moderate-to-very severe COPD and renal impairment in the TONADO ® studies

Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies

Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat ® device for maintenance treatment of COPD: comparison with the long-acting β 2 -agonist formoterol

Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol

Effects of epinephrine and vasopressin on median fibrillation frequency and defibrillation success in a porcine model of cardiopulmonary resuscitation

Reflux Disease, Gastrointestinal Ulcer or Weight Loss in Patients with COPD

Release of endogenous vasopressors during and after cardiopulmonary resuscitation

The Performance of Electroencephalogram Bispectral Index and Auditory Evoked Potential Index to Predict Loss of Consciousness During Propofol Infusion

Assessment of the safety and tolerance of 6% hydroxyethyl starch (200/0.5) solution : A randomized, controlled epidemiology study

Suchergebnisse filtern